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Abstract 
Introduction and aims: Nonalcoholic fatty liver disease (NAFLD) has become highly prevalent, 
paralleling the pandemic of obesity and diabetes, and represents an important burden. Nutrition 
knowledge is fundamental, in prevention, evolution and treatment of NAFLD. Association of low serum 
levels of vitamin D (VD) with several diseases, including NAFLD, has been emphasized in the last decade. 
We evaluated how serum levels of VD correlate with the presence of hepatic steatosis, and VD intake, in 
a random sample of the Portuguese adult population. 
Methods: Participants underwent a dietary intake inquiry, using a semi-quantitative food frequency 
questionnaire representative of the usual intake over the previous year. Anthropometric measures, 
blood tests and ultrasound were done. Hepatic steatosis was quantified according to Hamaguchi’s 
ultrasonographic score (steatosis defined by a score ≥ 2). 
Results: We recruited 789 adult individuals, 416 males (52.7%), mean age of 49.9 ± 17.0 years (18-79). 
Prevalence of hepatic steatosis was 35.5%, and after exclusion of excessive alcohol consumption, 28.0%. 
Mean VD serum levels were 26.0 ± 9.8 ng/ml and 68.4% participants had serum VD levels below 30 ng/ml. 
Mean serum levels of VD were not significantly different between participants with steatosis vs. no 
steatosis: 25.2±8.7 vs. 26.4±10.3 ng/ml, respectively (p=0.071). There was no correlation between VD 
serum levels and VD intake, measured by the FFQ, r=0.075 (p= 0.383). 
Conclusions: In spite of a high prevalence rate, there was no evidence that decreased VD serum levels 
were associated with hepatic steatosis. No significant correlation was found between VD dietary 
ingestion and VD serum levels. 
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Introduction 
Nonalcoholic fatty liver disease (NAFLD) 
emerged in the last decades as a leading cause of 
abnormal liver tests and chronic hepatic disease, 
paralleling the rising prevalence of diabetes, obesity, 
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metabolic syndrome (MS), over-nutrition and 
sedentary lifestyle, all of which known as risk factors 
for NAFLD. Although with great differences 
worldwide, between 25% and 45% of the general 
population, at least in some western countries and in 
selected populations [1-3], have NAFLD. In some of 
them, by circumstances still not completely 
understood, the disease will progress with hepatic 
inflammation, ballooning and fibrosis, composing 
nonalcoholic steatohepatitis (NASH), a known 
condition characterized by an important risk for 
cirrhosis, hepatocellular carcinoma, and/or liver 
failure. These two facts together concur to the 
possibility that NAFLD may become the major 
etiology of chronic liver disease and need for liver 
transplantation, in a near future. In spite of 
achievements in the understanding of the disease, 
there are, however, several unresolved issues, whose 
enlightening is fundamental for diagnosis and 
treatment. 
Vitamin D (VD) is a secosteroid hormone mainly 
synthesized in skin by action of ultraviolet B sunlight 
radiation in 7-dehydrocholesterol (Vitamin D3), and 
in a lesser percentage obtained from diet, especially 
oily fish and egg yolk (vitamin D2) [4]. The hormonal 
active form, 1,25-dihydroxyvitamin D, [1,25(OH)2D3], 
is obtained after two hydroxylations, of both vitamin 
D2 and vitamin D3, in liver [25(OH)D3] and kidney 
[5]. Since [25(OH)D3] has a long half-life and rather 
stable serum levels, it is usually the form measured in 
blood samples [6]. VD cellular effects are mediated by 
a nuclear receptor (VDR), member of nuclear 
hormonal receptor present in a large variety of 
different cells and organs, and not only in the bone 
tissue [6, 7]. 
Although VD only has an established role in 
bone health, there has been an enormous interest in 
the potential non-skeletal benefits of VD. Many 
recently published studies evidenced pleiotropic 
effects of VD, for instance in innate and adaptive 
immune system [8-10], or in cellular differentiation 
and proliferation, with possible participations in 
epidermal proliferation, apoptosis and DNA repair 
[11, 12]. It was also shown an inverse relation between 
VD levels and presence of diabetes [13, 14], with a 
possible interaction with β cells [15, 16], as well as a 
positive correlation between VD levels and 
adiponectin [17-20]. Animal studies demonstrated 
that hypovitaminosis D decreases islet beta cell 
function and insulin sensitivity, contributing to loss of 
glycaemic control, and suggests that VD modulates 
hepatic, glucose and lipid metabolism and promotes 
pancreatic islet function and survival [21, 22], 
attributing to VD, a role in prevention and 
management of obesity-induced type 2 diabetes 
mellitus and NAFLD. 
Furthermore, several observational studies 
associated low levels of VD with insulin resistance 
(IR), the MS [23], and cardiovascular diseases [24, 25]. 
Similarly, NAFLD/NASH patients had lower levels 
of VD than controls in two meta-analysis [26, 27]. 
Furthermore, one study reported that among patients 
with NAFLD, low VD is associated with worse liver 
histology [28]. VD was also shown to have a 
repressive effect on type I collagen formation in 
human stellate cells, with a potential effect on hepatic 
fibrosis regression [29]. However, other studies did 
not corroborate the suggested association between 
low serum levels of VD and NAFLD [30-32]. In one of 
these studies, neither the presence of insufficiency 
(20–30 ng/ml) nor deficiency (< 20 ng/ml) was 
associated with more severe liver histology on liver 
biopsy [30]. Despite some benefit of VD 
supplementation in patients with IR [14], as well as in 
rats with diet induced steatohepatitis [33], no benefit 
was found in individuals with normal glucose 
tolerance [34]. 
In spite of some epidemiological and 
experimental evidence of association between VD 
deficiency and NAFLD, the true relevance of 
hypovitaminosis D in NAFLD, and the real direction 
of a possible association between them, is still a matter 
of debate that needs to be clarified. Until now, no data 
was available from the population of Portugal, a 
southern European and sunny country. 
The main goal of the present study was to 
evaluate how the serum levels of VD vary with the 
presence of hepatic steatosis and how they are 
associated with VD intake, using a large sample of the 
general Portuguese population. 
Methods 
Study cohort 
We carried out a nationwide voluntary 
population-based cross-sectional study, using a 
random cluster sampling. The study population 
included Portuguese adults resident in the mainland 
(18-79 years old). The selection of the population for 
this study was performed on the basis of a random 
selection of two ACES [Agrupamentos de Centros de 
Saúde (Groups of Primary Care Settings)], out of five 
Nomenclature of Territorial Units for Statistics II 
regions, of mainland Portugal (Northern, Central, 
Lisbon and Tagus Valley, Alentejo, and Algarve). 
Within each ACES a second random selection of four 
primary care settings was performed. 
The study was approved by the national 
commission for protection of citizens personal data 
(“Comissão Nacional de Protecção de Dados”). 
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This study was conducted according to the 
guidelines laid down in the Declaration of Helsinki 
and all procedures involving human subjects were 
approved by the Ethical Committee of Coimbra 
Medical School (CE-15/2012). Written informed 
consent was obtained from all subjects. 
Study collection 
The study was carried out between 2012 and 
2015, in different seasons of the year (spring/summer 
and autumn/winter). After selection, individuals 
were invited by letter to participate in the study, 
which was designed to assess the prevalence of 
cardiovascular risk factors in the Portuguese 
population. Participation was about 35%, 
corresponding to 1685 participants. The study 
participants were then invited to participate in a 
sub-study on the prevalence of hepatic steatosis (HS) 
and viral hepatitis. 
After written informed consent was obtained, 
blood samples were collected and a questionnaire was 
used to characterize socio-demographic data (sex, age, 
district of residence, birthplace, race), anthropometric 
variables (weight, height, and waist circumference), 
living habits of alcohol consumption, smoking, and 
level of physical activity. 
The participants were evaluated after a 12-hour 
fast. Data was collected including biographic data, 
past medical history, medication, smoking and 
exercise habits (applying the “International Physical 
Activity Questionnaire: 12-Country Reliability and 
Validity”) [35], complete physical examination with 
abdominal circumference, and Body Mass Index 
(BMI). 
Complete biochemical tests were evaluated in all 
participants, including serum insulin and VD levels 
(Electro-chemiluminescence binding assay-ECLIA). VD 
serum levels, were adopted from the Endocrine 
Society Practice Guideline, that defines VD 
insufficiency as 25-(OH)D serum levels between 21 
and 29 ng/mL, and deficiency serum levels less than 
20 ng/mL [36]. Insulin resistance, was calculated by 
HOMA-IR test [37], and the presence of MS was 
calculated using the criteria proposed by the 
American Heart Association/National Heart, Lung, 
and Blood Institute Scientific Statement 
(AHA/NHLBI) criteria [38]. 
Diabetes was assumed in the participants with 
past medical history of treated diabetes, or, with a 
confirmed fasting glycaemia above 126 mg/dl (WHO. 
Definition and diagnosis of diabetes mellitus and 
intermediate hyperglycemia. At, http://www. 
who.int/diabetes/publications/Definition and 
diagnosis of diabetes_new.pdf) and a glycated 
hemoglobin level of 6.5% or superior (WHO. Use of 
Glycated Haemoglobin (HbA1c) in the Diagnosis of 
Diabetes Mellitus. At http://www.who.int/diabetes/ 
publications/report-hba1c_2011.pdf). 
The assessment of the dietary intake was done 
with a semi-quantitative food frequency 
questionnaire (FFQ), validated for the Portuguese 
population [39], and applied by an experienced 
nutritionist, with help from of a photographic manual 
as a visual support to allow the choice of multiples 
and sub-multiples of each portion, representative of 
the usual intake over the previous year. For detailed 
nutrient analysis, the Food Processor Plus Program 
version 5.0 (ESHA Research, Salem, OR, USA) was 
used, based on values from the US Department of 
Agriculture. In addition, values for typical Portuguese 
foods were computed using the Portuguese tables of 
food composition. Average alcoholic consumption 
and evidence of harmful drinking and dependence 
was assessed with the AUDIT (Alcohol Use Disorders 
Identification Test) questionnaire. Excessive alcohol 
intake was defined as daily alcohol consumption 
more than 20 g for women, and more than 30 g, for 
men. For statistical analysis purpose, participants 
were distributed in three different groups: absence of 
alcohol consumption, moderate drinkers (less than 
20g/day in women and 30/day in men), and 
excessive drinkers (above those limits) [40, 41]. 
To diagnose HS, an imagiological method was 
elected, as all participants were evaluated in tertiary 
centers, with availability of US and experienced 
operators. HS was quantified according to 
Hamaguchi’s ultrasonography score (0-6) with 
presence of steatosis defined by a score ≥ 2 [42], using 
a SIEMENS S 2000 with a 4 MHz probe. All operators, 
rigidly following Hamaguchi´s criteria, did imaging 
evaluation and the results were confirmed by a staff 
radiologist. 
Statistics 
Multiple linear regression was used to determine 
the predictor factors of serum VD. The method was 
validated by a Durbin-Watson statistic=1.94, with no 
collinearity between the independent variables, since 
VIF (Variance Inflaction Factor) was 1.92. 
Comparisons using hepatic steatosis as an 
independent factor were performed by a Student’s t 
test, considering the sample size and that dependents 
were not assimetrically distributed. Pearson’s 
correlation coefficient was used to access correlation 
between serum VD and its intake. 
Statistical analysis was performed using SPSS 
23.0, with a significance level of 0.05. 
Results 
We enrolled 789 participants, 416 males (52.7%), 
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with a mean age of 49.9 ± 17.0 years (from 18 to 79 
years old). Characteristics of the studied cohort are 
summarized in Table 1. The majority of participants 
were Caucasians (97.8%). 
HS was present in 35.5% of the participants, and 
excluding those with harmful alcohol consumption 
(>20g/day in females and >30g/day in males), the 
prevalence was 28%. HS was more prevalent in men 
(44.7%), than in woman (25.2%), and was associated 
with older age (55.9 vs. 46.6 years, respectively, 
p<0.001). 
 
Table 1. Characteristics of the study population (n=789) 
Age (years) 49.9 ± 17.0 (18-79) 
Gender: male (%) 416 (52.7 %) 
BMI (Kg/m2) 27.0 ± 4.8 
Waist circumference (cm) 93.0 ± 12.9 
Race (Caucasians; %) 772 (97.8%) 
Systolic BP (mm Hg) 127.9 ± 21.35 
Diastolic BP (mm Hg) 80.3 ± 11.2 
Hepatic steatosis (all participants) 280 (35.5 %) 
Hepatic steatosis (without excessive alcohol 
  
139 (28.0 %) 
Serum vitamin D (ng/ml):  
Mean±SD (range) 25.9 ± 9.8 (4.9–70.0) 
 < 20 ng/ml (n, %) 227 (28.8%) 
 21-29 ng/ml (n, %) 313 (39.7%) 
 > 30 ng/ml (n, %) 249 (31.6%) 
Total cholesterol (mg/dl) 197.38 ± 37.57 
Triglycerides (mg/dl) 111.1 ± 76.4 
HDL (mg/dl) 56.2 ± 15.4 
LDL (mg/dl) 122.36 ± 34.67 
Glycaemia (mg/dl) 94.93 ± 22.53 
Insulin Resistance, HOMA Test > 2.5 (n, %) 268 (34.0%) 
Metabolic syndrome n (%) 156 (19.8%) 
Diabetes mellitus n (%) 71 (8.9%) 
Glomerular Filtration Rate (GFR):  
 > 90 ml/minute (n, %) 589 (74.7%) 
 60-90 ml/minute (n, %) 182 (23.1%) 
 < 60 ml/minute (n, %) 18 (2.3%) 
Smokers (n, %) (proportion who ever smoked) 128 (16.2%) 
Legend: * Females: <20g/day; Males: <30g/day. Vitamin D: deficiency (<20 
ng/ml), insufficiency (21-29 ng/ml), recommended (> 30 ng/ml). 
 
As shown in table 2, presence of steatosis was 
associated mainly with the features of the MS and 
excessive alcohol ingestion. 
There were also no significant differences in 
serum VD levels between males and females: 26.2 ± 
9.4 ng/ml and 25.7 ± 10.2 ng/ml, respectively. Only 
31.6% participants had serum VD above 30 ng/ml. 
Furthermore, there were no differences between mean 
VD serum levels of the participants evaluated in 
spring/summer and those who were evaluated in 
autumn/winter (p=0.785). 
Mean serum VD levels were 26.0±9.8 ng/ml 
(min: 5.0; max: 70.0). Mean serum levels of VD were 
not statistically different in participants with steatosis 
vs. no steatosis: 25.2±8.7 vs. 26.4±10.3 ng/ml, 
respectively (p=0.071) (Figure 1). In participants with 
serum VD levels below 20 ng/ml, the prevalence of 
HS was 36.6%, in those with serum VD 21-29 ng/ml 
was 39%, and in those with serum VD above 30 ng/ml 
was 30.1%. There was a non-significant trend for less 
HS in participants with serum VD above 30 ng/ml 
(p=0.086). 
 
Table 2. Comparison of metabolic parameters with presence or 
absence of hepatic steatosis 
 Steatosis n Mean SD p 
Age No 509 46.5 17.4 <0.001 
Yes 280 55.9 14.4  
Vitamin D (ng/ml) No 509 26.4 10.3 0.071 
Yes 280 25.1 8.7  
BMI (kg/m2) No 509 25.5 3.9 <0.001 
Yes 280 29.7 4.8  
Waist (cm) No 508 88.5 11.3 <0.001 
Yes 279 101.2 11.3  
SBP No 509 123.6 20.8 <0.001 
Yes 280 135.4 20.2  
DBP No 509 78.0 10.6 <0.001 
Yes 280 84.2 10.9  
Insulinemia 
(µUI/ml) 
No 489 8.8 4.5 <0.001 
Yes 269 13.5 7.6  
HOMA – IR No 489 2.0 1.2 <0.001 
Yes 269 3.5 2.2  
Glycemia (mg/dl) No 509 90.6 19.4 <0.001 
Yes 280 102.7 25.5  
AST (U/L) No 507 19.9 8.8 <0.001 
Yes 279 22.1 8.8  
ALT (U/L) No 507 18.4 9.2 <0.001 
Yes 280 25.8 15.5  
Total Cholesterol 
(mg/dl) 
No 509 194.5 35.7 0.004 
Yes 280 202.5 40.2  
HDL Cholesterol 
(mg/dl) 
No 509 59.1 15.0 <0.001 
Yes 280 50.9 14.8  
LDL Cholesterol 
(mg/dl) 
No 509 119.4 31.8 0.002 
Yes 280 127.6 38.7  
Triglyceridemia 
(mg/dl) 
No 509 91.7 41.9 <0.001 
Yes 280 146.2 106.6  
Alcohol (g/day) No 507 20.1 30.3 <0.001 
Yes 278 35.8 38.5  
Legend: BMI: Body Mass Index. SBP: systolic blood pressure. DBP: diastolic blood 
pressure. HOMA – IR: Insulin resistance index assessed by the Homeostatic Model 
Assessment. AST: aspartate aminotransferase. ALT: alanine aminotransferase. HDL 
Cholesterol: High Density Lipoprotein. LDL Cholesterol: Low-density lipoprotein 
Cholesterol 
 
 
 
Figure 1. Serum vitamin D levels according to hepatic steatosis (p=0.071) 
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There was no direct correlation between BMI 
and VD serum levels (r = -0.193), although 
participants with BMI higher than 30 kg/m2 had 
significantly lower VD levels than those with BMI 
between 25 and 30 kg/m2 or less than 25 kg/m2 (p < 
0.001) (Figure 2). 
 
 
Figure 2. Correlation between BMI and serum vitamin D. 
 
VD serum levels were associated with the 
presence of MS, only in participants without HS, 
(p<0.001). In participants with HS, there was no 
association between VD and the MS (p=0.065) (Figure 
3 and table 3). 
 
 
Figure 3. Correlation between, serum vitamin D, hepatic steatosis and 
metabolic syndrome. 
 
Of the 789 participants, 71 had diabetes (8.9%). 
No significant difference was found in serum VD 
levels between those with or without diabetes, 23.9 
±9.3 vs 26.2±9.9 ng/ml (p=0.059), respectively. 
Among the 280 participants with HS, prevalence of 
diabetes was 17.1%, but again no significant 
difference was found between serum VD levels 
among those with or without diabetes, 24.1±9.6 ng/ml 
vs 25.4±8.6 ng/ml (p=0.154), respectively. 
As shown in table 4, we did not found 
correlation of different levels of alcohol consumption, 
with VD deficiency and HS, in our group. 
 
Table 3. Correlation of serum vitamin D with metabolic 
syndrome (MS) in presence or absence of hepatic steatosis (HS) 
HS MS n  Mean 
(ng/ml) 
SD SE 
(mean) 
p 
No No 462 Serum VD 
(ng/ml) 
26.89 10.383 0.483 0.001 
Yes 46 21.69 8.555 1.261  
Yes No 168 Serum VD 
(ng/ml) 
25.95 9.010 0.695 0.065 
Yes 110 23.95 8.395 0.800  
Legend: HS: hepatic steatosis, MS: metabolic syndrome, SD: standard deviation, 
SE: standard error 
Table 4. Correlation of serum vitamin D with hepatic steatosis 
and alcohol consumption 
Alcohol consumption Steatosis 
n 
Vitamin D deficiency 
n % p 
Null No 186 59 31.7% 0.340 
Yes 57 22 386%  
W: 0-20g/d; M: 0-30g/d No 172 48 27.9% 0.463 
Yes 82 27 32.9%  
W: >20g/d; M: > 30g/d No 149 35 23.4% 0.891 
Yes 139 34 24.4%  
Legend: Only 785 participants with serum vitamin D, alcohol consumption and 
hepatic steatosis. Vitamin D deficiency: < 20 ng/mL. W: women, M: men. 
 
 
No correlation was found between VD serum 
levels, and VD intake, measured by the FFQ, r=0.075 
(p=0.383) (figure 4). 
There was no correlation of physical activity 
with HS (p=0.619). 
The correlation of physical activity with serum 
VD levels, had no statistical significance, in the all 
study group (p=0.316), as in the those with serum VD 
below 20 ng/ml, between 21-29 and above 30 ng/ml 
(p=0.454). The separate analysis of serum VD levels, 
and physical activity, in those with, and without HS, 
was also with no statistical significance (respectively 
p=0.682 and p=0.193). 
Only 57 participants (7.2%), had serum VD less 
than 12 ng/ml, 18 of them with HS. We analyzed 
those participants separately, and the comparison 
between them and those with serum VD levels above 
12 ng/ml, for the presence of HS, did not show any 
statistically significant difference (p=0.587). 
Discussion 
Liver plays a determinant role in regulation of 
metabolic homeostasis, glucose and lipid 
metabolisms, and their abnormalities, ultimately 
generate hepatic triglyceride accumulation. VD has 
been referred with a signaling role in hepatic insulin 
sensitivity and pancreatic islet insulin secretion. 
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Figure 4. Correlation between serum vitamin D and VD intake, measured by 
the FFQ, r=0.075 (p=0.383). 
 
This information provides a scientific basis for 
establishing the benefits of the maintenance, or 
dietary manipulation of adequate vitamin D status in 
the prevention and management of obesity-induced 
T2DM and non-alcoholic fatty liver disease. 
The main results of our study suggest that in the 
Portuguese general population the serum levels of VD 
are not significantly lower in individuals presenting 
hepatic steatosis. This finding does not corroborate 
the findings that low VD serum levels may be a risk 
factor for steatosis. 
The decision of diagnose HS using ultrasound, 
instead of liver biopsy, considered the gold standard 
method to diagnose NAFLD, and distinguish it from 
NASH, is that liver biopsy is unsuitable for large scale 
studies, due to its invasive nature with possible 
important side effects, needing hospital admission, at 
least for a short period, and with elevated costs [43]. 
In addition, at least in some cases, steatosis is not 
uniformly distributed, and as the sample represents 
only about 1:50 000 of the liver, it could provide some 
misdiagnosis [44]. MRI or CT have great sensitivity, 
but its cost makes them inappropriate to use in large 
samples. Even though US has limited sensitivity 
namely to steatosis under 20%, it is the preferred 
first-line diagnostic procedure to diagnose HS, since it 
provides additional diagnostic information and is 
widely accepted as adequate to large scale studies [1, 
41, 45, 46]. Even with a low sensitivity of US to 
diagnose HS, the prevalence of HS in the Portuguese 
adult population, is in the higher range of the 
proclaimed rates, for an Occidentalized (or Western) 
population [1]. 
HS is related with the features of the MS, 
excessive weight and obesity, which by them have 
been associated with hypovitaminosis D, creating the 
doubt of a possible intermediation of VD as a co-factor 
for HS. 
Despite lower serum VD levels in obese 
participants, we did not find a direct correlation 
between higher BMI, and VD serum levels. Our 
results, do not agree with published data, reporting 
an association of obesity with VD deficiency, related 
with VD deposition in body fat, diminishing VD 
serum bioavailability, namely in obese people [47-49]. 
VD role in insulin secretion is known [50-52], 
and impaired glucose tolerance and DM2, were 
related with lower 25-OH(D), in different populations 
[53, 54], or in winter, when hypovitaminosis D is more 
prevalent [55]. Despite biological plausibility, 
available data are also currently insufficient to 
support recommendation of vitamin D 
supplementation, in order to a better glucose control, 
until new scientific evidence [4, 14]. 
Some animal studies, suggested that VD (and 
possibly other molecules such as nitric oxide) may act 
as anti-inflammatory mediators, released by skin, 
after sunlight-derived ultraviolet radiation (UVR), or 
preventing IR, MS, liver inflammation and 
progression to NASH [33, 56-58]. In our population, 
usually exposed to more than 2500 hours of sun/year 
a year, or even more in southern regions, we did not 
find statistical correlation of serum VD values with 
the time of the year of blood samples collection. Also, 
we did not find significant correlation of serum VD 
levels and physical exercise, in those with and 
without HS. 
In recent years, interest in VD has increased 
significantly, as a result of two kinds of published 
evidence. First, VD was implicated in other conditions 
apart from the known classical role on calcium 
homeostasis and bone tissue health, like 
cardiovascular diseases, IR, cancer, autoimmune 
diseases and all-cause mortality [59-61]. Second, 
several epidemiological studies emphasized the 
evidence that VD deficiency may have pandemic 
proportions, affecting a very large proportion of the 
population worldwide [62, 63]. The NHANES III 
(Third National Health and Nutrition Examination 
Survey, 1988-2004), reported VD levels below 30 
ng/ml in 77% in North Americans [64], and a recent 
study from different European northern and southern 
countries, data collected in winter and summer in 
more than 55 000 Europeans (adults and children), 
reported VD levels less than 12 ng/ml (considered 
deficiency) in 13% of the population, and less than 20 
ng/ml in 40% [63].  
Although there are differences in study design or 
population groups, seasonality, and laboratory 
method that can influence prevalence rates [65], it is 
peculiar that so large percentage of general 
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population would have VD deficits. In fact, it was 
recently and rightfully questioned the basis for 
consideration of thresholds for serum VD deficiency 
levels [66]. Reference values for serum VD were 
primarily set by bone and calcium needs, and are still 
a matter of debate if those recommendations can be 
extended to other conditions or to every population 
groups possibly influenced by VD deficiency [66]. 
Misclassifying VD deficiency could lead to under or 
over diagnoses, a matter of great relevance because 
supplementation with VD, although rarely in usual 
therapeutic recommended prescriptions, can lead to 
toxicity (namely hypercalcemia, hyperphosphatemia, 
suppressed parathyroid hormone, hypercalciuria and 
renal stones), and sun exposure can increase risk of 
skin cancer [67]. 
The Endocrine Society, in its Practice Guideline 
[36], defines VD deficiency as total serum 25-(OH)D 
levels of less than <20 ng/mL and VD insufficiency as 
21-29 ng/mL. In the same year, a publication of the 
Institute of Medicine (IOM) [4], assuming minimal 
sun exposure, states that total serum 25-(OH)D levels 
of 16 ng/mL, meet the needs of approximately half of 
the population, and levels of 20 ng/mL, or greater, 
meet the needs of nearly all of the population. 
Deficiency symptoms may appear with levels less 
than 12 ng/ml, depending upon a range of factors, 
and some people are potentially at risk for inadequacy 
with serum 25-(OH)D levels from 12 up to 20 ng/ml. 
Those recommendations are directed mainly to 
preservation of bone health. As far as cardiovascular 
diseases are concerned, type 2 diabetes mellitus or 
MS, the IOM did not find enough evidence to support 
VD intake recommendations for prevention, or 
disease development. 
Independently of the considerations of 
“normality” of VD serum levels it can be argued that 
lower levels of VD were found to correlate with the 
presence of NAFLD, MS or diabetes, in individual 
studies as well as in meta-analysis [26, 27]. The issue 
we are raising is if that association is causal or just a 
grouping of risk factors, or in some cases a 
consequence, such as in advanced liver disease. 
The definition of normality thresholds for VD is 
of great importance for interpretation of our results. 
In fact, in accordance with the IOM, 28% of the 
participants could be at risk of deficiency, and 7.2% 
would have deficiency, less than 12 ng/ml in our 
population. However, even considering this low 
cut-off, we still did not find any significant difference 
in VD serum levels according to the presence of 
hepatic steatosis (p=0.587). 
Other finding of our study, was that there was 
no significant correlation between serum VD levels 
and VD intake, measured by the FFQ. That may be 
related to the effect of sun exposure, able to overcome 
the effect of nutrient intake, or the data retrieved from 
the questionnaire. It is well known that food 
questionnaires have a wide error range, either due to 
the difficulties of participants recalling their intake or 
to having a false perception of their food intake, 
particularly in obese individuals [68-70].  
The strength of our study is that we studied a 
large, unbiased sample of the general population, 
allegedly healthy, living in a country with an average 
of 2500 hours of sun/year. The weaknesses are related 
to the reliability and accuracy usually related to all 
food questionnaires, as well the use of ultrasound for 
detection of hepatic steatosis. Also, it is difficult to 
extrapolate these findings from a normal population, 
where the presence of steatosis was an incidental 
finding, to patients that are seeking medical attention 
because they have hepatic steatosis. 
Conclusion 
Our results support that VD deficiency per se 
does not constitute a risk factor for HS. They need to 
be confirmed in different populations, but raise the 
question about the prescription Vitamin D 
supplementation in this setting, unjustified in the 
majority of cases or even harmful for some. 
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